Compounds > enisoprost
Page last updated: 2024-12-10

enisoprost

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5311219
CHEMBL ID266979
SCHEMBL ID564012
MeSH IDM0154087

Synonyms (26)

Synonym
81026-63-3
enisoprost (usan/inn)
D03999
enisoprost
enisoprostum [latin]
prosta-4,13-dien-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (4z,11alpha,13e)-(+-)-
enisoprost [usan:inn]
(+-)-methyl (z)-7-((1r,2r,3r)-3-hydroxy-2-((e)-(4rs)-4-hydroxy-4-methyl-1-octenyl)-5-oxocyclopentyl)-4-heptenoate
sc 34301
CHEMBL266979
sc-34301 ,
methyl (z)-7-[(1r,2r,3r)-3-hydroxy-2-[(e)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]hept-4-enoate
unii-j85f4k48q1
j85f4k48q1 ,
enisoprostum
SCHEMBL564012
enisoprost [mart.]
enisoprost [inn]
(+/-)-methyl (z)-7-((1r,2r,3r)-3-hydroxy-2-((e)-(4rs)-4-hydroxy-4-methyl-1-octenyl)-5-oxocyclopentyl)-4-heptenoate
enisoprost [usan]
prosta-4,13-dien-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (4z,11.alpha.,13e)-(+/-)-
Q27281331
methyl (z)-7-((1r,2r,3r)-3-hydroxy-2-((e)-4-hydroxy-4-methyloct-1-en-1-yl)-5-oxocyclopentyl)hept-4-enoate
CS-0024822
HY-105052
DTXSID201021627

Research Excerpts

Bioavailability

We studied the immunosuppressive properties of new, synthetic, prostaglandin E1 (PGE1) methyl ester analogs. We examined the hypothesis that the orally bioavailable PGE analogue enisoprost would improve renal function in renal transplant recipients chronically exposed to CYA.

ExcerptReferenceRelevance
" We examined the hypothesis that the orally bioavailable PGE analogue enisoprost (EP) would improve renal function in renal transplant recipients chronically exposed to CYA."( A trial of the prostaglandin E1 analogue, enisoprost, to reverse chronic cyclosporine-associated renal dysfunction.
Cole, M; Hyndman, V; Knight, R; Lewis, R; Maddux, M; Mozes, MF; Pollak, R; Scott, E; Van Buren, C; Veremis, S, 1992)		0.78
" We studied the immunosuppressive properties of new, synthetic, prostaglandin E1 (PGE1) methyl ester analogs (misoprostol, enisoprost) with oral bioavailability using an allogeneic in vitro immunoassay."( The immunosuppressive properties of new oral prostaglandin E1 analogs.
Dumble, LJ; Maddux, MS; Moran, M; Pollak, R; Wiederkehr, JC, 1990)		0.49

Dosage Studied

There was a significant dose-response relationship for enisoprost for inhibition of stimulated acid output (P = 0.01). A dose- response effect for en isoprost was found for the mean nocturnal hydrogen ion activity and pH, as well as for maximum pH attained.

ExcerptRelevanceReference
" CYA dosing was fixed at existing levels."( A trial of the prostaglandin E1 analogue, enisoprost, to reverse chronic cyclosporine-associated renal dysfunction.
Cole, M; Hyndman, V; Knight, R; Lewis, R; Maddux, M; Mozes, MF; Pollak, R; Scott, E; Van Buren, C; Veremis, S, 1992)		0.55
" A dose-response effect for enisoprost was found for the mean nocturnal hydrogen ion activity and pH, as well as for maximum pH attained."( Twenty-four-hour intragastric measurements in twenty healthy subjects: effect of enisoprost, a novel and potent antisecretory and antipeptic synthetic E1 prostaglandin.
Brunet, K; Cook, DJ; Fisher, D; Kirdeikis, P; McCullough, HN; Pinchbeck, B; Simpson, I; Thomson, AB; Wildeman, RA; Zuk, L, 1988)		0.8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID177465Effect determining the diarrheagenic activity in rats1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and gastric antisecretory properties of alpha chain diene derivatives of misoprostol.
AID59837Gastric antisecretory activity was determined in food stimulated Pavlov dogs by intrapouch administration ig; Value ranges from 0.017-0.0321987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and gastrointestinal pharmacology of the 4-fluoro analogue of enisoprost.
AID59324Antisecretory activity after ig administration in histamine-stimulated gastric fistula dogs; Range is 0.3-1.01983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
Synthesis and gastric antisecretory properties of 4,5-unsaturated derivatives of 15-deoxy-16-hydroxy-16-methylprostaglandin E1.
AID60032Relative gastric antisecretory effect in histamine-stimulated Heidenhain Pouch (HP) dogs1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and gastric antisecretory properties of alpha chain diene derivatives of misoprostol.
AID177736Activity for diarrheagenic effect in rats by intragastric administration and the value ranges between 37-771989Journal of medicinal chemistry, May, Volume: 32, Issue:5
18-cycloalkyl analogues of enisoprost.
AID60020Oral gastric antisecretory effect in histamine-stimulated Heidenhain Pouch (HP) dogs1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and gastric antisecretory properties of alpha chain diene derivatives of misoprostol.
AID177069Compound was evaluated for diarrheagenic side effects in adult male rats by intragastric administration1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of acyclic omega chain conjugated diene analogues of enisoprost.
AID59463Antisecretory activity after iv administration in histamine-stimulated Heidenhain pouch dogs; Range is 0.1-0.31983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
Synthesis and gastric antisecretory properties of 4,5-unsaturated derivatives of 15-deoxy-16-hydroxy-16-methylprostaglandin E1.
AID235589Ratio of ED50 of diarrheal effect to antisecretory effect1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
Synthesis and gastric antisecretory properties of 4,5-unsaturated derivatives of 15-deoxy-16-hydroxy-16-methylprostaglandin E1.
AID59834Gastric antisecretory activity in food stimulated pavlov dogs by intrapouch administration1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of acyclic omega chain conjugated diene analogues of enisoprost.
AID176830Tested for diarrheal side effects in rats by intragastric administration1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Chemistry and structure-activity relationships of C-17 unsaturated 18-cycloalkyl and cycloalkenyl analogues of enisoprost. Identification of a promising new antiulcer prostaglandin.
AID232582Ratio of ED50 value of diarrheal effect to that of ED50 value of antisecretory effect1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and gastric antisecretory properties of alpha chain diene derivatives of misoprostol.
AID224507Tested for gastric antisecretory activity in dogs by intrapouch administration1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Chemistry and structure-activity relationships of C-17 unsaturated 18-cycloalkyl and cycloalkenyl analogues of enisoprost. Identification of a promising new antiulcer prostaglandin.
AID229654Selectivity ratio was evaluated by the quotient of diarrheal ED50 value divided by antisecretory ED50 x 10 E-31992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of acyclic omega chain conjugated diene analogues of enisoprost.
AID176557Diarrheal effect after ig administration in rats1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
Synthesis and gastric antisecretory properties of 4,5-unsaturated derivatives of 15-deoxy-16-hydroxy-16-methylprostaglandin E1.
AID60725Intravenous gastric antisecretory activity against histamine-stimulated Heidenhain Pouch (HP) dogs at 1 ug/kg1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and gastric antisecretory properties of alpha chain diene derivatives of misoprostol.
AID185052Mucosal protective activity in rats was measured as minimum effective dose (MED); ig1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and gastrointestinal pharmacology of the 4-fluoro analogue of enisoprost.
AID59313Activity for gastric antisecretory activity in dogs by intrapouch administration and the value ranges between 0.017-0.0321989Journal of medicinal chemistry, May, Volume: 32, Issue:5
18-cycloalkyl analogues of enisoprost.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (24.32)18.7374
1990's27 (72.97)18.2507
2000's0 (0.00)29.6817
2010's1 (2.70)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.84 (24.57)
Research Supply Index3.83 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (21.62%)5.53%
Reviews1 (2.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (75.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
hydrogen carbonate
Bicarbonates: Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity.. hydrogencarbonate : The carbon oxoanion resulting from the removal of a proton from carbonic acid.		3.3611carbon oxoanioncofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
histamine
[no description available]		3.3511aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
1-anilino-8-naphthalenesulfonate
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.		1.9810aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe
theophylline
[no description available]		1.9810dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
azathioprine
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.		1.9810aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine		antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug
flurbiprofen
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.		1.9810fluorobiphenyl;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		3.3611aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
bromodeoxyuridine
Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.		1.9810pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
methylprednisolone
Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.		2.38206-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
tetradecanoylphorbol acetate
Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.		1.9810acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.3820benzenes;
phenyl acetates
8-bromo cyclic adenosine monophosphate
8-Bromo Cyclic Adenosine Monophosphate: A long-acting derivative of cyclic AMP. It is an activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase.. 8-Br-cAMP : A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP bearing an additional bromo substituent at position 8 on the adenine ring. An activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase.		1.98103',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
organobromine compound		antidepressant;
protein kinase agonist
bradykinin
[no description available]		1.9810oligopeptidehuman blood serum metabolite;
vasodilator agent
n-formylmethionine leucyl-phenylalanine
N-Formylmethionine Leucyl-Phenylalanine: A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated.. N-formyl-L-methionyl-L-leucyl-L-phenylalanine : A tripeptide composed of L-Met, L-Leu and L-Phe in a linear sequence with a formyl group at the amino terminus. It acts as a potent inducer of leucocyte chemotaxis and macrophage activator as well as a ligand for the FPR receptor.		1.9810tripeptide
tacrolimus
Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.		1.9710macrolide lactambacterial metabolite;
immunosuppressive agent
mercaptopurine
Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.		1.9710aryl thiol;
purines;
thiocarbonyl compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent
bilirubin
[no description available]		1.9810biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		4.0140prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
alprostadil
[no description available]		9.16348prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent
misoprostol
Misoprostol: A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties.. misoprostol : A diastereoisomeric mixture composed of approximately equal amounts of a double racemate of four of the sixteen possible diastereoisomers of methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate that is racemic prostaglandin E1 which is lacking the hydroxy group at position 15, but which has an additional hydroxy group at position 16. It is a synthetic prostaglandin E1 analogue, used in the treatment of gastric and duodenal ulcers. A weak abortifacient, it is also used for cervical ripening prior to surgical termination of pregnancy. The (11R,16S)-diastereoisomer is the pharmacologically active form.		5.23121
16,16-dimethylprostaglandin e2
16,16-Dimethylprostaglandin E2: A synthetic prostaglandin E analog that protects the gastric mucosa, prevents ulceration, and promotes the healing of peptic ulcers. The protective effect is independent of acid inhibition. It is also a potent inhibitor of pancreatic function and growth of experimental tumors.. 16,16-dimethylprostaglandin E2 : A prostanoid that is prostaglandin E2 in which both of the hydrogens at position 16 have been replaced by methyl groups. A synthetic analogue of prostaglandin E2, it is a potent inhibitor of pancreatic function and growth of experimental tumors. It also protects the gastric mucosa, prevents ulceration, and promotes the healing of peptic ulcers.		2.3920cyclopentanones;
monocarboxylic acid;
prostanoid;
secondary allylic alcohol		anti-ulcer drug;
gastrointestinal drug;
radiation protective agent
sc-46275
[no description available]		2.6730
nocloprost
nocloprost: phalloidin transport inhibitor		1.9810
vapiprost
vapiprost: thromboxane receptor antagonist; prostaglandin receptor antagonist		1.9810
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		1.9810aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
calcimycin
Calcimycin: An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports CALCIUM and other divalent cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems.		1.9810benzoxazole
cellulose
DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.		1.9710glycoside
bucladesine
Bucladesine: A cyclic nucleotide derivative that mimics the action of endogenous CYCLIC AMP and is capable of permeating the cell membrane. It has vasodilator properties and is used as a cardiac stimulant. (From Merck Index, 11th ed). bucladesine : A 3',5'-cyclic purine nucleotide that is the 2'-butanoate ester and 6-N-butanoyl derivative of 3',5'-cyclic AMP.		2.39203',5'-cyclic purine nucleotide
cyclosporine
Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).		6.1594
ConditionIndicatedRelationship StrengthStudiesTrials
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		03.0750
Primary Graft Dysfunction
A form of ischemia-reperfusion injury occurring in the early period following transplantation. Significant pathophysiological changes in MITOCHONDRIA are the main cause of the dysfunction. It is most often seen in the transplanted lung, liver, or kidney and can lead to GRAFT REJECTION.		02.9810
Acute Kidney Failure
[description not available]		02.9810
Acute Kidney Injury
Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.		02.9810
MODS
[description not available]		01.9810
Burns
Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.		02.6730
Multiple Organ Failure
A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.		01.9810
Dermatitis
Any inflammation of the skin.		01.9810
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		04.3322
Leucocythaemia
[description not available]		01.9810
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		01.9810
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		01.9810
Uremia
A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.		01.9810
Leukemia, Lymphocytic, T Cell
[description not available]		01.9810
Leukemia, T-Cell
A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.		01.9810
Diabetes Mellitus, Adult-Onset
[description not available]		01.9810
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		01.9810
Acute Kidney Tubular Necrosis
[description not available]		03.3611
Kidney Tubular Necrosis, Acute
Acute kidney failure resulting from destruction of EPITHELIAL CELLS of the KIDNEY TUBULES. It is commonly attributed to exposure to toxic agents or renal ISCHEMIA following severe TRAUMA.		03.3611
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		08.3611